Aphria to acquire CC Pharma for 24.5M euros
APHRIA INC. has proposed to acquired CC Pharma GmbH, a leading distributor of pharmaceutical products to more than 13,000 pharmacies in Germany. The transaction, when closed, will strengthen the company’s end-to-end medical cannabis operations and infrastructure in Ger-
many, a key market in Aphria’s international expansion. It is anticipated that the transaction will close in January, 2019. “This acquisition strengthens our foothold in Germany, one of the most highly sought-after medical cannabis markets in the world,” said Vic Neufeld, chief executive officer of Aphria. “CC Pharma is cash flow positive and has significant experience with regulatory requirements and international logistics. It will be a strong addition to Aphria’s presence in Germany, providing deeper access to the important pharmacist channel and advancing our ambitious global growth strategy.”
Founded in 1999, CC Pharma is a leading importer and distributor of European Union pharmaceuticals for the German market, with over 200 million euros in annual revenue. Aphria, through its subsidiary Aphria International, previously announced a supply agreement with CC Pharma to export approximately 1,200 kilograms of medical cannabis products from Canada to Germany. With Aphria’s experience as a global cannabis leader, the company will create a new division of CC Pharma dedicated to medical cannabis. CC Pharma operates a production, repackaging and labelling facility at its headquarters in Densborn.
“We are pleased to join forces with a premier global cannabis company, whose commitment to quality, safety and patient care closely aligns with our own. This is an exciting opportunity to build on our established network and advance our participation in a rapidly growing, emerging industry,” said Dr. Manfred Ziegler, managing director of CC Pharma.
The transaction will bolster Aphria’s growing presence in Germany, which includes a three-pronged approach covering demand, supply and distribution. Earlier this year, the company, through its wholly owned subsidiary Aphria Deutschland, acquired a 25.1-per-cent interest in Berlin-based Schoneberg Hospital, providing access to both doctors and patients to support education about the benefits of medical cannabinoids. It was also the first step in Aphria Germany’s plans to build and operate pain treatment centres throughout Germany.
To secure a constant delivery of imported cannabis for German patients, the company is building one of the biggest state-of-the-art GMP-certified (Good Manufacturing Practices) cannabis vaults in Bad Bramstedt, northern Germany, with a storage capacity of 5,000 kilograms. To prepare for in-country cultivation in Germany, Aphria is planning on building a research and development indoor growing facility in Neumunster, Germany.
“We are focused on leading the way in the medical cannabis market in Germany,” said Hendrik Knopp, managing director of Aphria Germany. “By combining Aphria’s expertise with CC Pharma’s established local market presence, we are well positioned to continue on that journey.”
Aphria will pay 24.5 million euros in cash to CC Pharma at closing, with an earnout multiple on future EBITDA (earnings before interest, taxes, depreciation and amortization) of up to another 23.5 million euros following closing, if certain performance milestones are met.
About Aphria Inc.
Aphria is a leading global cannabis company driven by an unrelenting commitment to its people, product quality and innovation. Headquartered in Leamington, Ont., the greenhouse capital of Canada, Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible.
We seek Safe Harbor.
Cole Cacciavillani, John Cervini, Arlene Dickinson, Shawn Dym, Robert Kozlov, Victor Neufeld, Renah A Persofsky, Dennis Staudt, Philip Waddington
(APHA) Shares: 249,751,622